PT3590960T - Remielinização estimulada por igg de nervos periféricos - Google Patents

Remielinização estimulada por igg de nervos periféricos

Info

Publication number
PT3590960T
PT3590960T PT191802370T PT19180237T PT3590960T PT 3590960 T PT3590960 T PT 3590960T PT 191802370 T PT191802370 T PT 191802370T PT 19180237 T PT19180237 T PT 19180237T PT 3590960 T PT3590960 T PT 3590960T
Authority
PT
Portugal
Prior art keywords
igg
peripheral nerves
remyelination
stimulated
stimulated remyelination
Prior art date
Application number
PT191802370T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PT3590960T publication Critical patent/PT3590960T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
PT191802370T 2012-02-29 2013-02-28 Remielinização estimulada por igg de nervos periféricos PT3590960T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261605117P 2012-02-29 2012-02-29

Publications (1)

Publication Number Publication Date
PT3590960T true PT3590960T (pt) 2023-04-18

Family

ID=47884569

Family Applications (2)

Application Number Title Priority Date Filing Date
PT191802370T PT3590960T (pt) 2012-02-29 2013-02-28 Remielinização estimulada por igg de nervos periféricos
PT137096756T PT2820042T (pt) 2012-02-29 2013-02-28 Remielinização estimulada por igg de nervos periféricos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT137096756T PT2820042T (pt) 2012-02-29 2013-02-28 Remielinização estimulada por igg de nervos periféricos

Country Status (21)

Country Link
US (5) US8986670B2 (cg-RX-API-DMAC7.html)
EP (2) EP2820042B1 (cg-RX-API-DMAC7.html)
JP (3) JP6335800B2 (cg-RX-API-DMAC7.html)
KR (3) KR102170615B1 (cg-RX-API-DMAC7.html)
CN (4) CN104302666A (cg-RX-API-DMAC7.html)
AR (2) AR090211A1 (cg-RX-API-DMAC7.html)
AU (3) AU2013203088B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014021240A2 (cg-RX-API-DMAC7.html)
DK (2) DK2820042T3 (cg-RX-API-DMAC7.html)
EA (2) EA032000B1 (cg-RX-API-DMAC7.html)
ES (2) ES2755056T3 (cg-RX-API-DMAC7.html)
FI (1) FI3590960T3 (cg-RX-API-DMAC7.html)
HK (1) HK1248534A1 (cg-RX-API-DMAC7.html)
IL (3) IL274512B2 (cg-RX-API-DMAC7.html)
MX (2) MX369444B (cg-RX-API-DMAC7.html)
NZ (1) NZ629867A (cg-RX-API-DMAC7.html)
PL (2) PL3590960T3 (cg-RX-API-DMAC7.html)
PT (2) PT3590960T (cg-RX-API-DMAC7.html)
SG (1) SG11201405302WA (cg-RX-API-DMAC7.html)
TW (3) TWI632158B (cg-RX-API-DMAC7.html)
WO (1) WO2013130826A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2820042T3 (da) * 2012-02-29 2019-10-28 Baxalta GmbH Igg-stimuleret remyelinisering af perifere nerver
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
CN111655336A (zh) 2017-11-17 2020-09-11 纽约州立大学研究基金会 使用x射线微束辐射治疗受损周围神经的方法
US20220111012A1 (en) * 2019-01-07 2022-04-14 Mallinckrodt Ard Ip Unlimited Company Methods of promoting remyelination
WO2025005230A1 (ja) * 2023-06-30 2025-01-02 富士フイルム株式会社 神経炎症の細胞間相互作用を評価する方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (cg-RX-API-DMAC7.html) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
DK166763B1 (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
AT376367B (de) 1983-03-16 1984-11-12 Immuno Ag Verfahren zur herstellung von therapeutisch verabreichbaren, in endbehaeltern abgefuellten plasmaderivaten
ATE36457T1 (de) 1983-05-02 1988-09-15 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen krankheitserregern.
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
AT390560B (de) 1986-05-30 1990-05-25 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンg結合活性を有する新規な蛋白質プロテインh、該蛋白質をコードする遺伝子及び該蛋白質の製造法
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
CA2089582A1 (en) * 1990-08-15 1992-02-16 Richard P. Bunge Autotransplantation of schwann cells to promote nervous system repair
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
WO1994013329A1 (de) 1992-12-16 1994-06-23 Immuno Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
HRP940645A2 (en) 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
BR9911131A (pt) 1998-06-09 2001-03-06 Statens Seruminstitut Processo para produção de imunoglobulinas para administração intravenosa e outros produtos de imunoglobulina
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
MXPA02011163A (es) * 2000-05-10 2004-08-19 Mayo Foundation Anticuerpos igm humanos con la capacidad de inducir remielinacion, y usos diagnosticos y terapeuticos de los mismos particularmente en el sistema nervioso central.
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
JP2003070465A (ja) * 2001-08-31 2003-03-11 Keio Gijuku シュワン細胞の培養方法
RU2412721C2 (ru) 2003-01-24 2011-02-27 Элан Фармасьютикалз Инк. Применение ремиелинизирующего средства для стимуляции нервных клеток при демиелинизирующем заболевании
JP2008500959A (ja) 2004-01-30 2008-01-17 スオメン プナイネン リスティ ヴェリパルヴェル ウイルスについて安全な免疫グロブリンの製造方法
EP1718675B2 (en) 2004-02-27 2017-01-25 Octapharma AG A method of providing a purified, virus safe antibody preparation
GEP20135853B (en) * 2007-02-02 2013-06-25 Univ Pierre And Marie Curie Method of myelination and oligodendrocyte differentiation promotion
US7854703B2 (en) 2007-09-25 2010-12-21 Intel Corporation Peripheral neuropathy detection
CA2643496C (en) 2008-11-06 2015-02-03 Michael Fehlings The therapeutic use of igg as a neuroprotective agent
CN102021140B (zh) * 2009-09-18 2013-04-24 上海市第一人民医院 一种分离、纯化许旺细胞的方法
DK2820042T3 (da) * 2012-02-29 2019-10-28 Baxalta GmbH Igg-stimuleret remyelinisering af perifere nerver

Also Published As

Publication number Publication date
AU2013203088B2 (en) 2015-12-03
TW201736398A (zh) 2017-10-16
KR20220045087A (ko) 2022-04-12
US10494418B2 (en) 2019-12-03
SG11201405302WA (en) 2014-09-26
DK2820042T3 (da) 2019-10-28
FI3590960T3 (fi) 2023-04-25
ES2755056T3 (es) 2020-04-21
PT2820042T (pt) 2019-10-31
AU2018200026B2 (en) 2019-12-05
MX2014010387A (es) 2015-09-25
US20200216518A1 (en) 2020-07-09
JP6637934B2 (ja) 2020-01-29
AR117207A2 (es) 2021-07-21
BR112014021240A2 (pt) 2018-09-18
JP2020059705A (ja) 2020-04-16
TW201400502A (zh) 2014-01-01
IL234303B (en) 2020-09-30
NZ629867A (en) 2016-09-30
IL274512B2 (en) 2024-07-01
KR20140134690A (ko) 2014-11-24
AU2016201137A1 (en) 2016-03-10
PL3590960T3 (pl) 2023-07-17
WO2013130826A3 (en) 2013-12-05
CN109966488A (zh) 2019-07-05
PL2820042T3 (pl) 2020-03-31
IL274512A (en) 2020-06-30
EP3590960B1 (en) 2023-03-29
HK1206035A1 (en) 2015-12-31
US20180291087A1 (en) 2018-10-11
US8986670B2 (en) 2015-03-24
CN104302666A (zh) 2015-01-21
JP6979990B2 (ja) 2021-12-15
US20210300997A1 (en) 2021-09-30
CN107551269A (zh) 2018-01-09
US20150232536A1 (en) 2015-08-20
AU2016201137B2 (en) 2017-10-12
EA201892521A1 (ru) 2019-07-31
AR090211A1 (es) 2014-10-29
ES2943585T3 (es) 2023-06-14
TWI632158B (zh) 2018-08-11
AU2013203088A1 (en) 2013-09-19
MX369444B (es) 2019-11-08
MX2019012496A (es) 2020-01-20
IL277103B2 (en) 2025-07-01
EP3590960A1 (en) 2020-01-08
TWI700297B (zh) 2020-08-01
DK3590960T3 (da) 2023-04-24
WO2013130826A2 (en) 2013-09-06
KR102673154B1 (ko) 2024-06-05
HK1248534A1 (zh) 2018-10-19
KR20200126005A (ko) 2020-11-05
IL277103A (en) 2020-10-29
KR102170615B1 (ko) 2020-10-28
AU2018200026A1 (en) 2018-01-25
EP2820042A2 (en) 2015-01-07
EP2820042B1 (en) 2019-07-24
JP2015508824A (ja) 2015-03-23
EA201400966A1 (ru) 2014-12-30
CN110343171A (zh) 2019-10-18
TW201838654A (zh) 2018-11-01
JP2018030856A (ja) 2018-03-01
US9834593B2 (en) 2017-12-05
IL274512B1 (en) 2024-03-01
EA032000B1 (ru) 2019-03-29
US20130224150A1 (en) 2013-08-29
JP6335800B2 (ja) 2018-05-30
IL277103B1 (en) 2025-03-01

Similar Documents

Publication Publication Date Title
CO7061086A2 (es) Combinaciones de compuestos activos
EP2844756A4 (en) MODULATION OF IMMUNE REACTIONS
LT2885010T (lt) Tautopatijos gydymo būdai
EP2839005A4 (en) MIRNA MODULATORS OF THERMOGENESIS
EP2807309A4 (en) ABFLUSSSIEB
CO7010838A2 (es) Compuestos de imidazopirrolidinona
EP2850106A4 (en) BISPECIFIC SCFV IMMUNOFUSION (BIF)
HUE037048T2 (hu) Eljárások 4-cikloalkiloxibenzolszulfonamidok elõállítására
EP2873047A4 (en) APPROVAL OF TRANSACTIONS
EP2814441A4 (en) WHEELCHAIR SUSPENSION
PT3068786T (pt) Compostos de pirazolopirimidina
AR092198A1 (es) Derivados de pirazolopirimidinas
BR112014022506A2 (pt) variantes de cbh1a
HRP20190030T1 (hr) Postupak pročišćavanja protutijela
IL277103A (en) IgG-stimulated remodeling of peripheral nerve myelin
EP2870086A4 (en) TRANSPORT BAR
EP2858975A4 (en) FBXO3 INHIBITORS
HUE045947T2 (hu) Formuláció IBS kezelésére
EP2940344A4 (en) SHOCK
EP2835558A4 (en) SHOCK
EP2892529A4 (en) USES OF (-) - PERHEXILINE
EP2820903A4 (en) WEAKENING OF INTERMEDIATE INTERFERENCE
EP2825662A4 (en) ENZYMATIC REMOVAL OF STERYL GLYCOSIDES
EP2842958A4 (en) NAPHTHOBISTHIADIAZOLDERIVAT
EP2842881A4 (en) DOSE COVER AND BEVERAGE CAN